ProMIS Neurosciences Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
with the thesis team here at Stifel, I am really excited to introduce Neil Warma, CEO and President of ProMIS Neurosciences. Do you want to maybe start with just a kind of overview of Yeah, of course.
what is going on? Yeah, no, thanks.
There is a lot going on. Thanks, Emily. Terrific conference as always. We are pleased to be invited, so thanks very much. Thanks for you attending in the audience as well. I will excuse my voice at the outset in case I need to break for a sip of tea or water. Thanks very much. Appreciate it. I am happy to. I am being represented here with Dr. Larry Altstiel, our Chief Medical Officer as well, who is responsible for a lot of the design and development of this program. My name, Neil Warma, President, CEO of ProMIS Neurosciences. I will walk through a few slides with you today, and I will give a kind of a summary, Emily, if that is okay, just to Yeah just to walk through the slides, and I can- Yeah interrupt, and you can interrupt me with questions as we go through.
Just to remind everybody, we are a publicly listed company. PMN is the ticker, so please review all of our SEC documents that we file online. As Emily said, there is a lot going on in ProMIS currently. We are a company that is focused on neurodegenerative diseases, and we are right now in the throes of a really exciting clinical trial in Alzheimer's disease, which reads out in a matter of months. We have said publicly that the Alzheimer's study reads out in Q1 of next year, so we are on the verge of finishing up patient dosing and final visits to get our data out in Q1. So early catalysts coming up for sure. We are well-funded. We did a significant financing a number of months ago with some of the top investors coming into the financing with Ally Bridge, Janus, Wellington, Deep Track.
So we are funded well beyond data through to beyond the end of next year. The company, ProMIS, is really based on our platform technology, protein misfolding. A little bit of a play on words, promise of novel drugs, but also the technology around misfolded proteins and their impact on a number of different diseases. And our ability, as we say here, EpiSelect is the platform, but our ability to selectively target misfolded forms of protein. So very selective approach to design of, very exquisite approach at designing antibodies, which differentiates us from, I believe, certainly in Alzheimer's, all other kind of drugs currently on the market or in development, even those that claim to be selective to oligomers.
Really, all of the others bind multiple different species of amyloid-beta. We believe we are the only drug that selectively binds the toxic oligomers. Should I Do you want me to continue through, or do you want to ask the questions back and forth? I am happy just to run through the slides, and if that is easiest for you, Emily.
Yeah. Maybe just since we've kind of paused right here.
Sure. Obviously, we recently got the data from Acumen that was a bit disappointing.
Maybe if you could just talk to us a little bit more about, more in detail, what you think, why you're different, and maybe point to any data that you can kind of show about why you think you are really selective for these oligomer species.
Of course. That's a good question. Yeah, the data that came out a week or so ago from our colleagues at Acumen, disappointing certainly for, first and foremost, for the patients. But again, just to be front and center, we put out a bit of a communique last week as well. There are clear differentiations between our PMN310 antibody and their antibody, and frankly, every other antibody, as I mentioned, out there. For one thing, ACU193, Acumen's antibody, is not purely selective to oligomers, although that's been the thesis all along, and they're big believers in it's the toxic oligomers that are driving cognitive decline, as we believe, as the folks at Eisai believe with lecanemab. It was designed to selectively target the oligomers, but at the end of the day, all the other antibodies, including ACU193, bind a multiple assortment of amyloid-beta species.
Not one is selective to the oligomers. The data that came out from Acumen doesn't really inform on the oligomer hypothesis because they bind multiple different species. The other thing, which is an important differentiator, if you look at the oligomer, because these are the toxic species of amyloid-beta protein, it's important in our minds, and I think most people's, not only to go in there and bind the oligomers to prevent them from further destruction, but also clear them and remove them from circulation from within the CSF. Because of that, we designed our antibody, which is actually similar to what lecanemab and donanemab did. We designed our antibody with an IgG1 background, not to get too immunological on you, but an IgG1 background provides for an immune response.
When the antibody binds to the oligomer, there is an immune response, there is a recruitment of microglia. The microglia come in, they bind the antibody-oligomer complex and remove oligomers from the CSF. It is not only neutralization, it is clearance of those antibodies. Acumen chose an IgG2 backbone, and an IgG2 does not elicit an immune response. So they do not have that clearance aspect. They go in and bind the oligomer, and they bind much weaker than we do, which is another differentiating factor. But they bind the oligomer, but they do not clear it. I think the two key differentiation points between us and all others, including Acumen, because I think Acumen is more like the other group, the two out there and other folks, rather than similar to us.
Their differences are the drug does not bind selectively the oligomers, and it has a different kind of mechanism of action, if you will, in not being able to clear the oligomers. The data really is important, Emily. When we look at the premise or the hypothesis supported by the data that we have communicated really for years now, that we believe it is the toxic oligomers, not plaque, and that is a whole other story, not plaque that is driving cognitive decline. As a result, we have got this elegant platform, because people say, "Well, if all the other people tried to design a selective antibody, and they end up binding all forms of amyloid-beta, how is it that you at ProMIS can actually do this?" Again, it comes to our EpiSelect platform.
I can probably advance some of these slides just to kind of show people what I mean here. But the EpiSelect platform really is an elegant way of us being able to predict how proteins are going to misfold. It is a conformational epitope, a three-dimensional epitope, to which we design an antibody against. So that epitope is only present on the misfolded form, the toxic oligomers. It is not present on monomers, and it is not present on plaque. Therefore, the design of the antibodies from the get-go, very different from the way other people design these antibodies. The data we have produced pre-clinically, we have tested, we have looked at multiple antibodies, including the Acumen antibody and donanemab, lecanemab, side by side to say, "What are the binding profiles of each of these? Are we differentiated with PMN310?
Are we true to our belief that we are not binding plaque?" I will come back to why that is really important, or not. We did side-by-side testing, and this slide here shows that the green shows the presence of plaque in brain sections of Alzheimer's patients, and the purple shows which antibodies are actually binding to the plaque. Every antibody here, except for PMN310, shows binding to plaque. With that, and we will come back to this in a minute, with that binding of plaque, not only is it not that relevant for preventing further cognitive decline, but clearing plaque is also associated with very serious side effects known as ARIA. ARIA essentially stands for bleeding and swelling on the brain.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
